HIGHLY CONFIDENTIAL. COPYING OR DISTRIBUTING STRICTLY PROHIBITED.1

Bank of America Merrill Lynch Healthcare Conference May 10, 2011

11

2

This presentation and any subsequent Q&A may contain “forward-looking” statements, including with respect to:Mylan’s anticipated earnings;Anticipated future financial and operating performance and results; andExpectations for our products and plans for growth.

These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to:

The impact of competition; Changes in third-party relationships; Changes in economic and financial conditions affecting the Company’s business; andUnexpected legal or regulatory challenges.

For more detailed information on the risks and uncertainties associated with the Company’s business activities, please see the Company’s Form 10-Q for the quarter ended March 31, 2011 and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update its forward-looking statements, whether as a result of new information, future events or otherwise.

Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with GAAP.

Please refer to Mylan’s earnings press release, dated February 24, 2011, for a reconciliation of certain non-GAAP financial measures included in this presentation to the most directly comparable financial measure calculated and presented in accordance with GAAP. This press release is available in the Investor Relations section of Mylan’s website. In addition, see the Company’s past quarterly earnings releases for additional GAAP to non-GAAP reconciliations, available at www.mylan.com.

Forward Looking Statements

3

North America Generics

43%

APAC20%

EMEA29%

Dey8%

Largest global generics business headquartered in the U.S.

2010 revenue: $5.5 billion 2010 Adjusted EBITDA: $1.4 billion

More than 1,000 products sold in more than 150 countries and territories

One of the industry’s broadest and highest quality portfolios

Demonstrated track record of historical growth with ongoing sustainable growth profile

Robust pipeline with ~1,000 submissions and ~500 launches annually

Matrix, one of the world’s largest API manufacturers

Dey Pharma, specialty branded pharmaceutical business

Mylan Institutional, newly created platform providing differentiated pharmaceutical products to institutional customers in North America

Workforce of ~16,000

The 3rd largest generics and specialty pharmaceutical company in the world

Company Overview

2010

Total Revenues: $5.5 billion

4

2011 Guidance & 2013 Strategic Growth Targets

(1) All guidance metrics except total revenue are stated on an adjusted basis which include synergy savings and exclude costs to attain synergies, intangibles amortization, imputed interest and other special items, to the extent applicable.

(2) Adjusted diluted EPS includes the impact of common shares upon conversion of the company’s mandatory preferred stock, as it was assumed to be more dilutive than the preferred stock dividend.

(3) Operating cash flow excludes certain special items.

201020112010 - 20132013ResultsGuidanceCAGRTargetsTotal Revenue$5,451[$6,100 - $6,300]15%~ $8,500Gross Profit Margin47%47% - 49%SG&A % of Revenue19%18% - 20%R&D % of Revenue5%5% - 6%EBITDA$1,3981,500 - 1,700Net Income$707825 - 875Diluted EPS$1.61$1.90 - $2.1020%~ $2.75Operating Cash Flow$781800 - 900Cash Interest Expense$271290 - 310Capital Expenditure$219250 - 300Tax Rate 27%26% - 28%

2010 2011 2010 - 2013 2013

Results Guidance CAGR Targets

Total Revenue $5,451 $6,100 - $6,400 15% $8,500

Gross Profit Margin 47% 47% - 49%

SG&A % of Revenue 19% 18% - 20%

R&D % of Revenue 5% 5% - 6%

EBITDA $1,399 $1,550 - $1,750

Net Income $707 $840 - $940

Diluted EPS $1.61 $1.90 - $2.10 20% $2.75

Operating Cash Flow $781 $800 - $900

Cash Interest Expense $271 $290 - $310

Capital Expenditures $193 $250 - $300

Tax Rate 27% 26% - 28%

Avg. Dil. Shares Outstanding (MM) 439 440 - 450

201020112010 - 20132013ResultsGuidanceCAGRTargetsTotal Revenue$5,451[$6,100 - $6,300]15%~ $8,500Gross Profit Margin47%47% - 49%SG&A % of Revenue19%18% - 20%R&D % of Revenue5%5% - 6%EBITDA$1,3981,500 - 1,700Net Income$707825 - 875Diluted EPS$1.61$1.90 - $2.1020%~ $2.75Operating Cash Flow$781800 - 900Cash Interest Expense$271290 - 310Capital Expenditure$219250 - 300Tax Rate 27%26% - 28%

$ million except EPS

Adjusted Metrics

5

North America GenericsQ1 2011 Results, Expected 2011 & 2012 Growth Drivers(USDm)

Targeting approximately 90 new product launches in 2011 15 U.S. launches expected to face limited competition – four launched to date (Sular,

Vfend, Precose and Femara)

Anticipated date certain generic product launches in 2011 & 2012:

Oral contraceptives: portfolio of 22 OCs launching in 2H 2011 through 1H 2014 (over next 2.5 yrs)

Full-year contribution from Bioniche Pharma Continued portfolio expansion, e.g. ophthalmics, topicals, antibiotics1) FTF or shared FTF opportunity

2) IMS MAT 12/10

2011 2012

Femara (launched)1

Effexor XR (June) Lexapro (Feb) Provigil (Apr)1 Zyprexa (Apr)

Levaquin (June) Uroxatral (July) Plavix (May) Clarinex 5mg (July)1 Actos (Aug)1

Caduet (Nov)1 Solodyn (Nov) Singulair (Aug)Singulair Chew (Aug)

Avalide (Sept)

Avandia (Sept) Diovan HCT (Sept)1 Actoplus Met (Dec)1

Atacand HCT (Dec)1

Targeting $5.5 billion2 of total market value

Targeting $23.7 billion2 of total market value

Q1 2011

Third Party Net Revenue

YoY CC growth$67422%

2010 & Q1 2011 Results: CY 2010

$2,36112%

6

EMEAQ1 2011 Results & 2011 Expected Growth Drivers(USDm)

Targeting approximately 360 country-level new product launches in 2011 Esomeprazole launched in first half of 2011

Anticipate more than 200 launches in the first half of 2011, contributing to stronger second half sales

Repatriation of 3rd party products remains on track to meet goal of 70% of former Merck Generics’ portfolio manufactured internally by end of 2013

Increase in percent of new products manufactured internally: From 15% in 2010 to greater than 50% in 2011

Continue to see significant opportunities from increased generic utilization rates throughout Europe

Q1 2011

Third Party Net Revenue

YoY CC growth$389-4%

2010 & Q1 2011 Results: CY 2010

$1,546-1%

7

Targeting approximately 50 new product launches in 2011 in Australia, New Zealand and Japan

Targeting more than 50 country-level launches of finished-dosage-form antiretroviral products, including Tenofovir-based products and innovative co-packs

Q1 2011

Third Party Net Revenue

YoY CC growth$27610%

2010 & Q1 2011 Results:

APACQ1 2011 Results & Expected Growth Drivers(USDm)

SpecialtyQ1 2011 Results & Expected Growth Drivers(USDm)

Continued growth of EpiPen® and Perforomist® franchises Continue to add complementary products to leverage current specialty

organization Launch of Combo product for treatment of COPD anticipated in 2015

Q1 2011

Third Party Net Revenue

YoY CC growth$9717%

2010 & Q1 2011 Results:

CY 2010

$1,07412%

CY 2010

$42318%1

1) Adjusted to exclude the impact of the transfer of certain generics products to North America in Q4 2009 that were previously sold to third parties by Specialty.

8

2010 @ ActualRates

Fx 2010 Price Volume / Mix New Products 2011 GuidanceMidpoint

2011: Top Line Growth AssumptionsTotal RevenueUSDm, at 2011 Budget Fx Rates Unless Otherwise Noted

Existing Products

mid-singledigit

decline

low-double

digitincrease

500+launchesglobally

Est. regional launches: NA: ~90 EMEA: ~360 APAC: 50+

Date Certain Gx launches:-Vfend-Femara-Effexor XR-Levaquin-Nexium (EMEA)

5,451

6,2501

Specialty ~20% yoy growth

Generics ~13% yoy growth

1) Midpoint of guidance range

-Uroxatral-Solodyn -Caduet

-Sular

Price Erosion Assumptions: U.S. mid-single digit decline EMEA high-single / low-double

digit decline

9

Q&A